rumor
    rumor
    • Screeners
    • Heatmaps
    • Charts
    • News
    • Documentation
    • Pricing
    • FAQ
    You're viewing limited data.
    Log inSign up

    Sign up

    24 hours of full access, free. No credit card.

    Log inPricing
    1 asset

    Market news

    TypeAll
    SortNewest
    Assets
    OCS
    Type
    TypeAll
    All
    Sort
    SortNewest
    Newest

    Filter by asset

      Wall Street Analysts Think Oculis Holding AG (OCS) Could Surge 384.89%: Read This Before Placing a Bet
      Nov 12Yahoo FinanceOCS
      Oculis at Stifel 2026 Healthcare Conference 2026: shift to neuroprotection
      Nov 11Investing.comOCSSF
      Oculis to Host In-Person and Virtual R&D Day: Advancing a Differentiated Late-Stage Development Pipeline
      Nov 9Yahoo FinanceOCS
      Down 21.1% in 4 Weeks, Here's Why Oculis Holding AG (OCS) Looks Ripe for a Turnaround
      Nov 6Yahoo FinanceOCS
      Oculis Holding AG (OCS) Reports Q3 Loss, Lags Revenue Estimates
      Nov 3Yahoo FinanceOCS
      Oculis Reports Q3 2026 Financial Results and Builds Momentum Toward Multiple Upcoming Pipeline Catalysts
      Nov 3Yahoo FinanceOCS
      Oculis Holding AG (OCS) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

      Oculis Holding AG (OCS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

      Nov 2Yahoo FinanceOCS
      Oculis Appoints Experienced Life Sciences Leader Björn Tackenberg, M.D., Ph.D., as Chief Scientific Officer to Advance Neurology Innovation

      Björn Tackenberg, M.D. Ph.D. FEAN FAAN, Professor of Neurology, will lead Oculis’ global integrated scientific strategy supporting the advancement of Privosegtor and its expansion into new therapeutic applications Aaron Tansy, M.D., appointed as Vice President, Development Franchise Head, Neurology, brings complementary expertise in neurology and global clinical development ZUG, Switzerland, November 2, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical com

      Nov 2Yahoo FinanceOCS
      Oculis to Feature Privosegtor’s Neuroprotective Potential and Ongoing PIONEER Program at APOIS Congress and CNS Summit

      Positive Phase 2 ACUITY trial findings support Privosegtor’s potential to deliver a first-in-class neuroprotective treatment for patients with optic neuritis and beyond ZUG, Switzerland, October 29th, 2026 -- Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced upcoming presentations highlighting Privosegtor’s neuroprotectiv

      Oct 29Yahoo FinanceOCS
      Oculis reports biomarker data from optic neuritis trial
      Oct 22Investing.comOCS
      Oculis Reports New Phase 2 ACUITY Biomarker Data Further Supporting Privosegtor’s Neuroprotective Potential in Optic Neuritis

      Privosegtor reduced post-onset increases in plasma neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) compared with placebo Lower NfL and GFAP levels provide objective, complementary biological evidence of reduced neuroaxonal injury and suppressed reactive astrogliosis Biomarker results support previously reported functional (LCVA) +18-letter gains and structural retinal preservation at Month 3, reinforcing Privosegtor’s development for acute optic neuritis and acute mult

      Oct 22Yahoo FinanceOCS
      H.C. Wainwright reiterates Oculis stock rating on trial progress
      Oct 21Investing.comOCS
      Oculis to present biomarker data from optic neuritis trial
      Oct 20Investing.comOCS
      Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting
      Oct 20Yahoo FinanceOCS
      Oculis to Present Late-Breaking Phase 2 ACUITY Biomarker Analyses of Privosegtor in Optic Neuritis at the 10th Joint ACTRIMS-ECTRIMS Meeting

      Presentation highlights new translational data evaluating plasma NfL and GFAP as biomarkers of neuroaxonal injury and neuroinflammation ZUG, Switzerland, October 20, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, today announced that new biomarker data from the Phase 2 ACUITY trial of Privosegtor will be featured in a late-breaking session at

      Oct 19Yahoo FinanceOCS
      Oculis Completes Randomization in PREDICT-1 Registrational Trial of Licaminlimab for TNFR1-Mediated Dry Eye Disease

      High-Responder Target Enrichment: 2/3 of the 176 enrolled patients carry the target TNFR1 genetic variant previously linked to enhanced clinical response in Phase 2 trials Precision Medicine Approach in a Large Market: Licaminlimab is positioned as a potential first-in-class precision medicine for an estimated 1.5+ million patients in the U.S. with moderate-to-severe TNFR1-mediated dry eye disease (DED)1-4, addressing a critical unmet need in a historically heterogeneous indication. Key Mileston

      Oct 19Yahoo FinanceOCS
      Oculis lýkur slembiröðun í PREDICT-1 skráningarrannsókninni á Licaminlimab við TNFR1-miðluðum augnþurrki
      Oct 19Yahoo FinanceOCS
      Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

      ZUG, Switzerland, Oct. 08, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the vesting and settlement of RSUs previously granted to a member of the Company’s Executive Committee and Board of Directors. Attachment Notification of managers' transaction - Riad Sherif - 5 October 2026 RSU vest

      Oct 8Yahoo FinanceOCS
      Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

      Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculi

      Oct 7Yahoo FinanceOCS
      Oculis to Highlight Licaminlimab at Eyecelerator @ AAO 2026 and Partner with Neuro-Ophthalmology Subspecialty Day

      Licaminlimab genotype-based precision medicine approach for TNFR1-mediated dry eye disease in PREDICT-1 registrational symptoms trial on track for topline readout around year-end ZUG, Switzerland, October 7, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announced that Riad Sherif, M.D., Chief Executive Officer of Oculi

      Oct 6Yahoo FinanceOCS
      Oculis Holding Announces Board Resignation of Long-Serving Director Lionel Carnot

      Detailed price information for Oculis Holding Ag (OCS-Q) from The Globe and Mail including charting and trades.

      Oct 1The Globe and MailOCS
      Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS

      Oculis and the National Multiple Sclerosis Society’s campaign share a common goal to accelerate breakthroughs in MS research and improve patients’ quality of life ZUG, Switzerland, October 1, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology, is partnering with the National Multiple Sclerosis Society on its Campaign to End MS, as the industry part

      Oct 1Yahoo FinanceOCS
      Oculis Announces Resignation of Lionel Carnot from Board of Directors

      ZUG, Switzerland, September 30, 2026 -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company focused on breakthrough innovations to address significant unmet medical needs in neuro-ophthalmology and ophthalmology, today announces that director Lionel Carnot will be resigning from the Board of Directors, effective today, after nearly a decade of dedicated service since 2017. Anthony Rosenberg, Chair of the Board, remarked: “On behalf of the B

      Sep 30Yahoo FinanceOCS
      Oculis Joins the National Multiple Sclerosis Society’s Campaign to End MS
      Sep 30Yahoo FinanceOCS
      Stifel reiterates Buy rating on Oculis stock, $40 target
      Sep 28Investing.comOCS
      After Plunging 24% in 4 Weeks, Here's Why the Trend Might Reverse for Oculis Holding AG (OCS)
      Sep 28Yahoo FinanceOCS
      Analysts Have Conflicting Sentiments on These Healthcare Companies: Aethlon Medical (AEMD), Xenon (XENE) and Oculis Holding (OCS)

      Detailed price information for Xenon Pharmaceuticals Inc (XENE-Q) from The Globe and Mail including charting and trades.

      Sep 19The Globe and MailAEMDOCS
      H.C. Wainwright raises Oculis stock price target to $39 on DED trial progress
      Sep 18Investing.comOCS
      Oculis Holding AG: Navigating Through Major Trial Setback (NASDAQ:OCS)
      Sep 17Seeking AlphaOCS
      Oculis Publishes Notifications of Transactions by Persons Discharging Managerial Responsibilities

      ZUG, Switzerland, Sept. 17, 2026 (GLOBE NEWSWIRE) -- The attached notification relates to the purchase of ordinary shares by a member of the Company’s Board of Directors. Attachment notification-of-managers-transaction-lionel-carnot-14-september-2026

      Sep 17Yahoo FinanceOCS
      Oculis at H.C. Wainwright conference: biomarker bet and neurology push
      Sep 14Investing.comOCS
      Wall Street Analysts Believe Oculis Holding AG (OCS) Could Rally 199.75%: Here's is How to Trade

      The mean of analysts' price targets for Oculis Holding AG (OCS) points to a 199.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

      Aug 31Yahoo FinanceOCS
      H.C. Wainwright reiterates Oculis stock rating on trial start
      Aug 25Investing.comOCS
      First Patient Treated in PIONEER-1 Registrational Trial of Privosegtor for Optic Neuritis
      Aug 24Yahoo FinanceOCS

      This is the newest page. Registered accounts read further back.